ClinicalTrials.gg
CompletedNCT05882045TRIUMPH-3Updated Jul 30, 2026

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

A Phase 3 interventional study of Retatrutide and Placebo in Obesity and Cardiovascular Diseases, sponsored by Eli Lilly and Company. Completed at 169 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,946
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.

Enrollment
2nd of 16
1,946 · median 392
Started
2023
with 5 others
Phase 3
9 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
15 of 16
Eli Lilly and Company

Among the 16 studies testing retatrutide in Obesity, this one is the 2nd largest by enrollment, is one of 6 that started in 2023, is one of 9 in phase 3, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing retatrutide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

03

Conditions studied

  • Obesity
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) ≥35.0 kilogram/square meter (kg/m²).
  • Have established cardiovascular (CV) disease with at least 1 of the following:

    • prior myocardial infarction
    • prior ischemic or hemorrhagic stroke, or
    • symptomatic peripheral arterial disease
  • Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.

Exclusion criteria

Exclusion Criteria:

  • Have had acute myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure within 90 days prior to screening.
  • Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
  • Have a prior or planned surgical treatment of obesity.
  • Have a change in body weight greater than 5 kg (11 pounds) within 90 days prior to screening.
  • Have Type 1 diabetes.
  • Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have had pancreatitis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,946 participants (actual)

Study arms

  • Experimental
    Retatrutide Dose 1

    Participants will receive retatrutide subcutaneously (SC).

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose 2

    Participants will receive retatrutide SC.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 80

Secondary outcomes

  1. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 80

  2. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 80

  3. Percent Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 80

  4. Percent Change from Baseline in Triglycerides

    Time frame: Baseline, Week 80

  5. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 80

  6. Change from Baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline, Week 80

  7. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 80

  8. Percent Change from Baseline in Fasting Insulin

    Time frame: Baseline, Week 80

  9. Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score

    Time frame: Baseline, Week 80

  10. Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)

    AUC is presented as a single average measure of AUC across the study duration.

    Time frame: Baseline to Week 80

07

Study locations

169 sites
  • Central Phoenix Medical Clinic
    Phoenix, Arizona 85020, United States
  • Valley Clinical Trials, Inc.
    Covina, California 91723, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • Valley Research
    Fresno, California 93720, United States
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
  • Velocity Clinical Research, Westlake
    Los Angeles, California 90057, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Velocity Clinical Research, Panorama City
    Van Nuys, California 91405, United States
  • Chase Medical Research, LLC
    Waterbury, Connecticut 06708, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Charter Research - Winter Park
    Orlando, Florida 32803, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii 96817, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Humphreys Diabetes Center
    Boise, Idaho 83702, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Great Lakes Clinical Trials - Gurnee
    Gurnee, Illinois 60031, United States
  • Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
    Springfield, Illinois 62711, United States
  • Brengle Family Medicine
    Indianapolis, Indiana 46260, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50265, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • MedVadis Research Corporation
    Waltham, Massachusetts 02451, United States
  • StudyMetrix Research
    City of Saint Peters, Missouri 63303, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • IMA Clinical Research Warren
    Warren Township, New Jersey 07059, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Carteret Medical Group
    Morehead City, North Carolina 28557, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • UPMC Montefiore University Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • Tribe Clinical Research, LLC
    Greenville, South Carolina 29607, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Tribe Clinical Research - Spartanburg
    Spartanburg, South Carolina 29301, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731, United States
  • Pinnacle Clinical Research
    Austin, Texas 78757, United States
  • South Texas Clinical Research
    Corpus Christi, Texas 78404, United States
  • Southern Endocrinology Associates
    Mesquite, Texas 75149, United States
  • Texas Diabetes & Endocrinology, P.A.
    Round Rock, Texas 78681, United States
  • Sleep Therapy Research Center
    San Antonio, Texas 78229, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Advanced Research Institute
    Ogden, Utah 84405, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Fundación Respirar
    Buenos Aires, Buenos Aires C1426ABP, Argentina
  • CEDIC
    CABA, Buenos Aires C1060ABN, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1056, Argentina
  • IDIM - Instituto de Investigaciones Metabólicas
    Ciudad de Buenos Aires, Buenos Aires C1012AAR, Argentina
  • MICA - Medicina e Investigación Cardiometabólica
    Del Viso, Buenos Aires 1669, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata
    Mar del Plata, Buenos Aires 7600, Argentina
  • DIM Clínica Privada
    Ramos Mejía, Buenos Aires B1704ETD, Argentina
  • Consultorio de Investigación Clínica EMO SRL
    Buenos Aires, Buenos Aires F.D. 1405, Argentina
  • Stat Research S.A.
    Buenos Aires, Buenos Aires F.D. C1023AAB, Argentina
  • Investigaciones Medicas Imoba Srl
    Buenos Aires, Buenos Aires F.D. C1056ABH, Argentina
  • Centro Médico Viamonte
    Buenos Aires, Buenos Aires F.D. C1120AAC, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
  • Centro Medico Privado CEMAIC
    Capital, Córdoba Province X5008HHW, Argentina
  • Instituto Médico DAMIC
    Córdoba, Córdoba Province 5003DCE, Argentina
  • Centro Medico Privado San Vicente Diabetes
    Córdoba, Córdoba Province 5006, Argentina
  • Centro de Salud e Investigaciones Médicas
    Santa Rosa, La Pampa Province 6300, Argentina
  • CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
    Godoy Cruz, Mendoza Province 5501, Argentina
  • Centro de Investigaciones Clínicas Baigorria
    Granadero Baigorria, Santa Fe Province 2152, Argentina
  • INECO Neurociencias Oroño
    Rosario, Santa Fe Province 2000, Argentina
  • Instituto de Investigaciones Clinicas Rosario
    Rosario, Santa Fe Province 2000, Argentina
  • Centro de Investigaciones Clinicas del Litoral
    Santa Fe, Santa Fe Province S3000FWO, Argentina
  • Sanatorio San Martin
    Venado Tuerto, Santa Fe Province 2600, Argentina
  • Sanatorio Norte
    Santiago del Estero, Santiago del Estero Province 4200, Argentina
  • Centro de Investigaciones Médicas Tucuman
    SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
  • Canberra Hospital
    Canberra, Australian Capital Territory 2605, Australia
  • Emeritus Research
    Botany, New South Wales 2019, Australia
  • Northern Beaches Clinical Research
    Brookvale, New South Wales 2100, Australia
  • Camden Hospital
    Camden, New South Wales 2570, Australia
  • The AIM Centre / Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • University of Sydney - Charles Perkins Centre
    Sydney, New South Wales 2006, Australia
  • Royal Brisbane and Women's Hospital
    Brisbane, Queensland 4029, Australia
  • Core Research Group
    Brisbane, Queensland 4064, Australia
  • CDH Research Institute
    Maroochydore, Queensland 4558, Australia
  • Logan Hospital
    Meadowbrook, Queensland 4131, Australia
  • Fusion Clinical Research
    Adelaide, South Australia 5000, Australia
  • Nightingale Research
    Adelaide, South Australia 5000, Australia
  • Southern Adelaide Diabetes & Endocrine Services
    Mount Gambier, South Australia 5290, Australia
  • Southern Adelaide Diabetes & Endocrine Services
    Oaklands Park, South Australia 5046, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Barwon Health
    Geelong, Victoria 3220, Australia
  • Austin Health - Repatriation Hospital
    Heidelberg West, Victoria 3081, Australia
  • One Clinical Research
    Nedlands, Western Australia 6009, Australia
  • BC Diabetes Office
    Vancouver, British Columbia V5Y 3W2, Canada
  • Discovery Clinical Services
    Victoria, British Columbia V8T 5G4, Canada
  • Joanne F. Liutkus Medicine Professional Corporation
    Cambridge, Ontario N3H 4L5, Canada
  • LMC Clinical Research Inc. (Thornhill)
    Concord, Ontario L4K 4M2, Canada
  • Dr. Steven V. Zizzo Research Professional Corporation
    Hamilton, Ontario L8J 0B6, Canada
  • Milestone Research Inc.
    London, Ontario N5W 6A2, Canada
  • North York Diagnostic and Cardiac Centre
    North York, Ontario M6B 3H7, Canada
  • Centricity Research Oshawa
    Oshawa, Ontario L1J 2K9, Canada
  • Kawartha Cardiology Clinical Trials
    Peterborough, Ontario K9J 0B2, Canada
  • Manna Research Toronto
    Toronto, Ontario M9W 4L6, Canada
  • Ecogene-21 - Cmas
    Chicoutimi, Quebec G7H 0S7, Canada

Showing the first 100 of 169 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Apr 2026, 34 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 34 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2023
First posted
May 31, 2023
StartActual
May 30, 2023
Primary completionActual
Apr 16, 2026
CompletionActual
May 14, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05882045
Responsible party
Sponsor
First posted
May 31, 2023
Start date
May 30, 2023
Primary completion
Apr 16, 2026
Completion
May 14, 2026
Last update
Jul 30, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion